A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Name: A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Published: 2023
License: Public Domain

Novartis Pharmaceuticals · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

breast-cancer

hormone receptor positive her2 negative breast cancer with a pik3ca mutation, breast cancer, non-interventional study, nis, alpelisib, fulvestrant, pass, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Related documents